Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,042,339 papers from all fields of science
Search
Sign In
Create Free Account
CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology
Known as:
QS-WPAI-SHP TEST
, WPAI01TN
, Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Name
Test names of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
W. Tillett
,
Chen-Yen Lin
,
Aubrey Trevelin Sprabery
,
J. Birt
,
A. Kavanaugh
Clinical and Experimental Rheumatology
2020
Corpus ID: 218891978
OBJECTIVES To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically…
Expand
2018
2018
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
R. Mesa
,
R. Boccia
,
+5 authors
B. Stein
Clinical Lymphoma, Myeloma & Leukemia
2018
Corpus ID: 52040059
Review
2017
Review
2017
SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors
A. Kavanaugh
,
R. Vender
,
+4 authors
P. Nash
2017
Corpus ID: 80140644
Background Ixekizumab (IXE), a monoclonal high affinity antibody that selectively targets interleukin-17A, was superior to…
Expand
2016
2016
Patient‐reported outcomes with the β3‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
V. Khullar
,
G. Amarenco
,
+4 authors
Z. Hakimi
Neurourology and Urodynamics
2016
Corpus ID: 9249623
To assess patient‐reported outcomes (PROs) in patients with overactive bladder (OAB) receiving the novel β3‐adrenoceptor agonist…
Expand
Highly Cited
2015
Highly Cited
2015
Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study.
W. Tillett
,
G. Shaddick
,
+11 authors
N. McHugh
Rheumatology
2015
Corpus ID: 38909313
OBJECTIVE The aim of this study was to determine the extent to which structural damage, clinical disease activity, demographic…
Expand
2014
2014
Workplace productivity and voice disorders: a cognitive interviewing study on presenteeism in individuals with spasmodic dysphonia.
Derek D. Isetti
,
Tanya K. Meyer
Journal of Voice
2014
Corpus ID: 25601249
Review
2013
Review
2013
Patient-Reported Cognitive Dysfunction Negatively Impacts Functioning in Patients with Major Depressive Disorder – Preliminary Findings from the Perform Study
D. Saragoussi
,
J. Haro
,
+6 authors
C. François
2013
Corpus ID: 72900271
Highly Cited
2008
Highly Cited
2008
The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC…
K. Coyne
,
C. Sexton
,
D. Irwin
,
Z. Kopp
,
C. Kelleher
,
I. Milsom
BJU International
2008
Corpus ID: 5372528
To examine the effect overactive bladder (OAB) and other lower urinary tract symptoms (LUTS) on health‐related quality of life…
Expand
2008
2008
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER
N. Zinner
,
L. Noe
,
L. Rasouliyan
,
T. Marshall
,
R. Seifeldin
Current Medical Research and Opinion
2008
Corpus ID: 10760476
ABSTRACT Objective: Assess changes in resource utilization, work and activity impairment, and health utility among OAB patients…
Expand
Review
2007
Review
2007
Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
D. Revicki
,
M. K. Willian
,
+6 authors
M. Okun
Journal of dermatological treatment (Print)
2007
Corpus ID: 41181916
Objective: The effect of adalimumab on patient‐reported outcomes (PROs) was evaluated in patients with moderate to severe…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE